ArticleChildren (Basel, Switzerland)2025
Is There a Relationship Between Serum BDNF Levels, Disease Severity, and Psychiatric Symptoms in Adolescents with Atopic Dermatitis?
Article in Children (Basel, Switzerland), 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
Abstract
BACKGROUND/
objectivesThis study aimed to investigate the relationship between serum brain-derived neurotrophic factor (BDNF) levels, disease severity, and various psychiatric symptoms in adolescents with atopic dermatitis (AD), compared to a healthy control group.
methodsThis study included 50 patients aged 10-18 years with AD, along with a control group matched for age and gender. Measurements included complete blood count, basal cortisol, serum immunoglobulin E (IgE), CRP, erythrocyte sedimentation rate, and serum BDNF levels. Disease severity was evaluated using the Eczema Area and Severity Index. Participants also completed several instruments: the Beck Depression Inventory-II, the Body Appreciation Scale, the Children's Dermatology Life Quality Index, the Pittsburgh Sleep Quality Index, and the Social Anxiety Scale for Children-Revised.
resultsThe AD group experienced a more impaired dermatological quality of life, lower body appreciation, more severe depressive symptoms, and poorer sleep quality compared to the control group. However, there was no significant difference between the groups in serum BDNF, basal cortisol, and CRP levels. Furthermore, serum BDNF levels showed no significant correlation with disease severity or psychosocial parameters in patients with AD.
conclusionsThe current findings do not suggest a link between serum BDNF levels and disease severity or psychiatric symptoms in adolescents with AD. Further research is necessary in this field.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.